The company said last night, “In addition to today’s medical leadership transition, we are announcing our plan to share an update of clinical data from the ongoing CRDF-004 trial on July 29, at which point we expect to release a substantive dataset.” The data is from Cardiff ‘s lead program in first-line RAS-mutated metastatic colorectal cancer. Shares of Cardiff Oncology (CRDF) are down 8%, or 30c, to $3.10 in premarket trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRDF:
Disclaimer & DisclosureReport an Issue
Source link